Session » Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)

Date: Saturday, November 6, 2021

Time: 2:00PM-3:00PM

Meeting: ACR Convergence 2021

2:00PM-2:15PM: Abstract Number: 0488

Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial

2:15PM-2:30PM: Abstract Number: 0489

CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases

2:30PM-2:45PM: Abstract Number: 0490

Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways

2:45PM-3:00PM: Abstract Number: 0491

Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study

« View all sessions from this meeting